Rallybio (RLYB)
(Delayed Data from NSDQ)
$1.10 USD
+0.01 (0.92%)
Updated Oct 3, 2024 03:59 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Rallybio Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 79 | 68 | 46 | 25 | 0 |
Income After Depreciation & Amortization | -79 | -68 | -46 | -25 | 0 |
Non-Operating Income | 6 | 2 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -73 | -66 | -46 | -25 | NA |
Income Taxes | 0 | 1 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | -2 | 0 | -2 | -2 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -75 | -67 | -47 | -26 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -75 | -67 | -47 | -26 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -82 | -68 | -46 | -25 | 0 |
Depreciation & Amortization (Cash Flow) | -3 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -79 | -68 | -46 | -25 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 40.45 | 31.82 | 25.52 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.84 | -2.09 | -1.84 | NA | NA |
Diluted Net EPS (GAAP) | -1.84 | -2.09 | -1.84 | NA | NA |
Fiscal Year end for Rallybio Corporation falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 17.34 | 19.79 | 21.11 | 19.37 | 20.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.04 | -19.79 | -21.11 | -19.37 | -20.08 |
Non-Operating Income | 1.29 | 1.44 | 1.48 | 1.64 | 1.67 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -15.75 | -18.34 | -19.63 | -17.73 | -18.41 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | -0.49 | -0.69 | -0.61 | -0.65 | -0.22 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.24 | -19.03 | -20.24 | -18.37 | -18.63 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.24 | -19.03 | -20.24 | -18.37 | -18.63 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 44.13 | 40.77 | 40.64 | 40.53 | 40.36 |
Diluted EPS Before Non-Recurring Items | -0.37 | -0.47 | -0.50 | -0.45 | -0.46 |
Diluted Net EPS (GAAP) | -0.37 | -0.47 | -0.50 | -0.45 | -0.46 |